JP2013514788A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514788A5
JP2013514788A5 JP2012545018A JP2012545018A JP2013514788A5 JP 2013514788 A5 JP2013514788 A5 JP 2013514788A5 JP 2012545018 A JP2012545018 A JP 2012545018A JP 2012545018 A JP2012545018 A JP 2012545018A JP 2013514788 A5 JP2013514788 A5 JP 2013514788A5
Authority
JP
Japan
Prior art keywords
protein
residues
kabat numbering
numbering system
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012545018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2010/001737 external-priority patent/WO2011075786A1/en
Publication of JP2013514788A publication Critical patent/JP2013514788A/ja
Publication of JP2013514788A5 publication Critical patent/JP2013514788A5/ja
Pending legal-status Critical Current

Links

JP2012545018A 2009-12-23 2010-12-23 イムノコンジュゲート及びその作製方法2 Pending JP2013514788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28949709P 2009-12-23 2009-12-23
US61/289,497 2009-12-23
PCT/AU2010/001737 WO2011075786A1 (en) 2009-12-23 2010-12-23 Immuno-conjugates and methods for producing them 2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017000559A Division JP6484259B2 (ja) 2009-12-23 2017-01-05 イムノコンジュゲート及びその作製方法2

Publications (2)

Publication Number Publication Date
JP2013514788A JP2013514788A (ja) 2013-05-02
JP2013514788A5 true JP2013514788A5 (enExample) 2014-02-13

Family

ID=44194832

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012545018A Pending JP2013514788A (ja) 2009-12-23 2010-12-23 イムノコンジュゲート及びその作製方法2
JP2017000559A Active JP6484259B2 (ja) 2009-12-23 2017-01-05 イムノコンジュゲート及びその作製方法2

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017000559A Active JP6484259B2 (ja) 2009-12-23 2017-01-05 イムノコンジュゲート及びその作製方法2

Country Status (8)

Country Link
US (1) US9315581B2 (enExample)
EP (1) EP2516462B1 (enExample)
JP (2) JP2013514788A (enExample)
KR (1) KR101961495B1 (enExample)
AU (1) AU2010336029B2 (enExample)
CA (1) CA2784610C (enExample)
SG (1) SG181814A1 (enExample)
WO (1) WO2011075786A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
TW201341401A (zh) * 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
GB201204014D0 (en) * 2012-03-07 2012-04-18 Univ Leeds Diagnostic marker compounds and their use
RU2501010C1 (ru) * 2012-07-25 2013-12-10 Федеральное государственное бюджетное учреждение "Государственный научный центр колопроктологии" Минздравсоцразвития России Способ прогнозирования неэффективности консервативной терапии язвенного колита
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CN110312549B (zh) 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
AU2018229277B2 (en) 2017-02-28 2025-03-20 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
IL277049B2 (en) 2018-03-13 2024-02-01 Zymeworks Bc Inc Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
WO2020191306A1 (en) 2019-03-21 2020-09-24 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
IL286846B2 (en) 2019-04-26 2025-06-01 Immunogen Inc Camptothecin derivatives
PH12022550348A1 (en) * 2019-08-15 2022-12-12 Janssen Biotech Inc Materials and methods for improved single chain variable fragments
KR20220045047A (ko) * 2019-08-19 2022-04-12 션양 파마슈티컬 유니버시티 항체 변이체 및 이의 적용
US12076400B2 (en) 2019-12-06 2024-09-03 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
CN115850449A (zh) * 2022-09-29 2023-03-28 苏州智核生物医药科技有限公司 抗体和缀合物
EP4612172A1 (en) * 2022-10-31 2025-09-10 National Research Council of Canada Improved engineered immunoglobulins and binding fragments

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623322A (en) 1899-04-18 Turret-lathe
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
NZ238473A (en) 1990-06-19 1993-11-25 Keith James Ross Lever lock having levers protected by an internal lever housing
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US20020193567A1 (en) 1995-08-11 2002-12-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
EP1078092B1 (en) 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US20030129192A1 (en) 1999-09-10 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1248800A2 (en) 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030104562A1 (en) 2000-02-11 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2002004685A1 (en) 2000-07-12 2002-01-17 California Institute Of Technology Method for determining three-dimensional protein structure from primary protein sequence
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2469941A1 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2002351896A1 (en) * 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
CN1646161A (zh) 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
CA2486490A1 (en) 2002-03-19 2003-12-31 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003087306A2 (en) 2002-04-05 2003-10-23 Agensys, Inc. Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
EP2233572A3 (en) 2002-06-06 2011-01-12 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
MXPA05001933A (es) 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Gタンパク質共役受容体およびその使用
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004045553A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004058309A1 (en) 2002-12-23 2004-07-15 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
EP1597558A2 (en) 2003-01-08 2005-11-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
US20040171823A1 (en) 2003-01-14 2004-09-02 Nadler Steven G. Polynucleotides and polypeptides associated with the NF-kappaB pathway
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
US20060228710A1 (en) 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US20070292416A1 (en) 2003-06-02 2007-12-20 Alexion Pharmaceuticals, Inc. De-Immunized Anti-Cd3 Antibody
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
CA2567655C (en) 2004-06-02 2015-06-30 Diatech Pty Ltd Binding moieties based on shark ignar domains
EA010374B1 (ru) 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006116076A2 (en) * 2005-04-28 2006-11-02 Genencor International, Inc. Tab molecules
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
MX2009003938A (es) * 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
MX338775B (es) * 2009-06-04 2016-05-02 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them

Similar Documents

Publication Publication Date Title
JP2013514788A5 (enExample)
JP2012531212A5 (enExample)
CN110144009B (zh) Cd47单域抗体及其用途
CA3007021C (en) Anti-pd-l1 single domain antibody and use thereof
CN109096395B (zh) 阻断型cd47纳米抗体及其用途
CN109096401B (zh) 抗Her2纳米抗体及其编码序列和用途
JP6449441B2 (ja) FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物
CA2861307C (en) High affinity sirp-alpha reagents
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
JP2016500655A5 (enExample)
CN112533633A (zh) Cd4的抗原结合构建体
JP2012518425A5 (enExample)
JP2009100745A5 (enExample)
EP4257605A1 (en) Anti-tslp nanobody and use thereof
JP7007758B2 (ja) 癌の予後と診断における放射性標識抗pd-l1ナノボディの応用
JP2010523096A5 (enExample)
JP2013535191A5 (enExample)
JP2014515600A5 (enExample)
EP3404042B1 (en) Monoclonal antibody fnab8 and application thereof
AU2020212534A1 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2021047386A1 (zh) 靶向caix抗原的纳米抗体及其应用
CN118240082A (zh) Pd-1结合分子及其应用
WO2021197358A1 (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途
EP4326779A1 (en) Anti-fibroblast activation protein antibodies
CN114685667B (zh) 间皮素结合分子及其应用